AbbVie Inc. (NYSE:ABBV) is now up 4.16% compared to a 12-month low of $65.06. We have seen the price to move 1.65% higher and get settled at $67.76 on 7/26/2019. At recent session, it appeared stuck in a range of $67.37 to $69.14. This company shares are 25.32% off its target price of $84.92 and the current market capitalization stands at $100.28B. The recent change has given its price a -9.39% deficit over SMA 50 and -32.4% deficit over its 52-week high. The stock witnessed -0.35% declines, -14.98% declines and -15.87% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ABBV’s volatility during a week at 1.79% and during a month it has been found around 2.21%.

What Does AbbVie Inc. (ABBV) Do?

The company describes itself in regulatory filings as, “AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson’s disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on January 1, 2013 and is headquartered in North Chicago, IL.” [Text can be found here: under company description.]

AbbVie Inc. (ABBV) Top Holders

Institutional investors currently hold around $69.69 billion or 71% in ABBV stock. Look at its top three institutional owners: Capital Research Global Investors owns $9.93 billion in AbbVie Inc., which represents roughly 9.9% of the company’s market cap and approximately 14.25% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 120,844,140 shares of the stock are valued at $8.19 billion. The third largest holder is Blackrock Inc., which currently holds $6.45 billion worth of this stock and that ownership represents nearly 6.43% of its market capitalization.

AbbVie Inc. 13F Filings

At the end of March reporting period, 947 institutional holders increased their position in AbbVie Inc. (NYSE:ABBV) by some 62,380,381 shares, 974 decreased positions by 74,623,730 and 234 held positions by 891,432,170. That puts total institutional holdings at 1,028,000,000 shares, according to SEC filings. The stock grabbed 117 new institutional investments totaling 6,752,662 shares while 135 institutional investors sold out their entire positions totaling 4,151,978 shares.

AbbVie Inc. (NYSE:ABBV) Insider Trades

Multiple company employees have indulged in significant insider trading. AbbVie Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director AUSTIN ROXANNE S has acquired 11,500 shares of AbbVie Inc. (ABBV) in the trading session dated Jun. 26, 2019. These shares are worth $776,250 and were traded at $67.5 each. The SEC filing shows that CHASE WILLIAM J performed a purchase of 30,400 shares. The EVP, Finance & Administration added these shares by way of transaction on Jun. 26, 2019. The company’s shares were assimilated at $67.3 per share worth to an investment of some $2,045,920 to the account of CHASE WILLIAM J.

Director, RAPP EDWARD J, purchased 7,500 common shares of AbbVie Inc. (ABBV) in the open market. In a transaction dated Jun. 26, 2019, the shares were bought at an average price of $67.3, giving away a sum of $504,750. After this purchase, 30,662 common shares of ABBV are directly owned by the insider, with total stake valued at $2,077,657.

In the transaction dated Mar. 25, 2019, a great number of shares sold came courtesy the VP, Controller; Durkin Brian L disposed a total of 475 shares at an average price of $79.69, amounting to approximately $37,853. The insider now directly owns 9,374 shares worth $635,182.

AbbVie Inc. (ABBV) Analyst Guide

Several analysts have released their opinion on AbbVie Inc. (NYSE:ABBV), with 2 analysts believing it is a strong buy. Whereas 9 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.54 average brokerage recommendation [T1].